Eleven Biotherapeutics, Inc. (EBIO) Trading Up 10.4%
Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) shares were up 10.4% during trading on Monday . The stock traded as high as $0.80 and last traded at $0.74. Approximately 6,061,900 shares changed hands during mid-day trading, an increase of 1,262% from the average daily volume of 445,089 shares. The stock had previously closed at $0.67.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Spark Investment Management LLC bought a new position in Eleven Biotherapeutics in the 2nd quarter worth approximately $148,000. Virtu KCG Holdings LLC bought a new position in Eleven Biotherapeutics in the 2nd quarter worth approximately $175,000. Vanguard Group Inc. boosted its holdings in Eleven Biotherapeutics by 17.4% in the 2nd quarter. Vanguard Group Inc. now owns 206,450 shares of the biopharmaceutical company’s stock worth $324,000 after buying an additional 30,600 shares during the period. Finally, Municipal Employees Retirement System of Michigan bought a new position in Eleven Biotherapeutics in the 3rd quarter worth approximately $382,000. 4.91% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY WARNING: “Eleven Biotherapeutics, Inc. (EBIO) Trading Up 10.4%” was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this article on another site, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The correct version of this article can be viewed at https://www.watchlistnews.com/eleven-biotherapeutics-inc-ebio-trading-up-10-4/1719162.html.
About Eleven Biotherapeutics
Eleven Biotherapeutics, Inc is a preclinical-stage biopharmaceutical company. The Company applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company’s product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema (DME) and uveitis.
Receive News & Ratings for Eleven Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eleven Biotherapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.